Life Science Leader - Home Page
LIFE SCIENCE LEADER CONTENT COLLECTIONS. Adapting With Automation: A Guide For The Modern Lab. Vaccine Maker's Toolkit: Strategies For Manufacturing And Supply Management. Scaling Cell and Gene Therapies. Your Supply Chain On Inflation: An Outsourcing Analysis. Improving Diversity In Clinical Trials.
New Leadership At The Cancer Research Institute
Sep 27, 2024 · Dr. Alicia Zhou, Ph.D., the new CEO at the Cancer Research Institute (CRI), aims to bring her experience in academia and the West Coast health tech startup scene to bear on a 70-year-old nonprofit institution with deep roots in cancer immunotherapy. Her experience using Big Data to improve molecular therapeutics, in both the academic and ...
Exploring Functional Uses Of AI In Life Sciences
Mar 19, 2024 · The future of AI in the life sciences industry has transformative potential in many different sectors. AI will significantly speed up the creation of personalized treatments and drug discovery, shortening the journey from research to clinical use. Advancements in AI will lead to more accurate medical diagnostics and extend healthcare services ...
Ahead Of The Curve On Radiopharmaceuticals - Life Science Leader
Jan 1, 2024 · Despite the negatives – a complicated supply chain, short half-life, and the radioactive fear factor – analysts are forecasting continued growth in radiopharmaceuticals (from approximately $5-7 billion in 2022 to $9-$13 billion in 2032), amid a shift in focus from diagnostics to therapeutics. In late December, Bristol Myers Squibb announced ...
Where Are They Now? SQZ Biotech - lifescienceleader.com
May 1, 2024 · In 2020, Sharei took SQZ Biotech public with a $71 million IPO, and channeled the funds into its pipeline of novel cell therapies. Being the founder and CEO of SQZ Biotech was Sharei’s first full-time job, and it was “all-consuming,” noted Sharei in the 2019 article. “People often applaud entrepreneurship, lionize its leaders, and paint ...
Companies To Watch: Antiva Biosciences - Life Science Leader
Feb 27, 2024 · Antiva Biosciences is developing a new drug, coded ABI-2280, for treating Human Papilloma Virus (HPV)-related diseases, including precancerous conditions. ABI-2280 is a prodrug of an acyclic nucleoside phosphonate, formulated to improve safety as well as enhance deliverability as a topical medicine. The drug is now in early to mid-stage ...
MD's I270 Biotech Corridor: A Hub Within A Hub - Life Science …
Nov 7, 2018 · Known as the I-270 corridor, it includes Montgomery and Frederick counties and is home to 140 life sciences companies that employ 19,000 people, according to 2017 state labor statistics. “People, ideas, and products are moving up and down the I-270 corridor,” says Richard Griffin, director of economic development for the City of Frederick.
The Ozempic Dilemma What Makes A Dual Brand Approach Viable
Feb 5, 2024 · The dual brand approach for denosumab is based on dosing differences – Prolia is administered at 60 mg every six months whereas Xgeva is administered at 120 mg once every four weeks. Although Prolia is less expensive than Xgeva on an annual basis, the cost of Xgeva per mg is lower than Prolia. While using Xgeva in osteoporosis patients may ...
Where Are They Now? Karuna Therapeutics - lifescienceleader.com
Jan 1, 2024 · However, Paul was confident about the drug’s potential success and innovative attributes, a sentiment echoed in the company’s stock price. Now: On December 22, 2023, Bristol Myers Squibb (BMS) announced that it would acquire Karuna Therapeutics, and its promising neuroscience portfolio (including KarXT), in a deal worth $14 billion.
How Pharma Executives View Future Business Travel
Aug 2, 2021 · By Rob Wright and Dan Schell. In May 2021, Industry Standard Research (ISR) conducted a web-based quantitative survey of 154 pharmaceutical/biotech industry participants. The goals of the study included: understanding the barriers to restarting business travel. assessing comfort level with traveling for business in the wake of the pandemic.